DATE: 2/9/2020
TO: Health Alert Network
FROM: Rachel Levine, MD, Secretary of Health

DISTRIBUTION: Statewide
LOCATION: n/a
STREET ADDRESS: n/a
COUNTY: n/a
MUNICIPALITY: n/a
ZIP CODE: n/a

This transmission is a “Health Advisory”: provides important information for a specific incident or situation; may not require immediate action.

HOSPITALS: PLEASE SHARE WITH ALL MEDICAL, PEDIATRIC, NURSING AND LABORATORY STAFF IN YOUR HOSPITAL; EMS COUNCILS: PLEASE DISTRIBUTE AS APPROPRIATE; FQHCs: PLEASE DISTRIBUTE AS APPROPRIATE LOCAL HEALTH JURISDICTIONS: PLEASE DISTRIBUTE AS APPROPRIATE; PROFESSIONAL ORGANIZATIONS: PLEASE DISTRIBUTE TO YOUR MEMBERSHIP; LONG-TERM CARE FACILITIES: PLEASE SHARE WITH ALL MEDICAL, INFECTION CONTROL, AND NURSING STAFF IN YOUR FACILITY

The Pennsylvania Department of Health (DOH) is releasing the following directions based on guidance released by the Centers for Disease Control and Prevention (CDC) for risk assessment and management of healthcare personnel with potential exposure to patients with 2019 novel coronavirus.

- This guidance provides a framework for classifying HCP exposures as high, medium, low, and no identifiable risk.
- It applies to HCP with exposure to patients with confirmed 2019 novel coronavirus or PUIs when test results are not available within 72 hours.
- Risk is determined by factors such as the duration of exposure, the patient’s clinical symptoms (e.g., coughing), whether the patient was masked, whether aerosol generating procedures were done, and type of PPE used.
- HCP with high or medium risk exposures will be excluded from work and will require monitoring for development of symptoms for 14 days.
- HCP with low risk exposures (i.e., close contact with appropriate PPE) will require monitoring for symptoms but should not be excluded from work.
- Clinical evaluation and treatment of a PUI or confirmed case must be done in coordination with DOH (1-877-PA-HEALTH) or your local health department. This will include a discussion of occupational health risk.

Background
CDC is closely monitoring an outbreak of respiratory illness caused by a novel (new) coronavirus (named by the World Health Organization as “2019-nCoV”) that was first detected in Wuhan, Hubei Province, China and which continues to expand. Chinese health officials have reported tens of thousands of infections with 2019-nCoV in China, with the virus spreading from person-to-person in many parts of that country. Transmission to healthcare personnel (HCP) in China has also been reported in the media; however, there is not yet detailed information about those transmission events. Infections with 2019-nCoV, most of them associated with travel from Wuhan, are also being reported from a growing number of international locations, including the United States. The first confirmed instance of person-to-person spread of 2019-nCoV in the United States was reported on January 30, 2020.

Much is unknown about 2019-nCoV. Current knowledge is largely based on what is known about similar coronaviruses. Coronaviruses are a large family of viruses that are common in humans and in many different species of animals, including camels, cattle, cats, and bats. Rarely, animal coronaviruses can infect people and then spread between people such as with SARS-CoV, MERS-CoV, and likely now with 2019-nCoV.

Early reports suggest spread from person-to-person most likely happens during close exposure to a person infected with 2019-nCoV. Person-to-person spread may occur similar to other coronaviruses, mainly via respiratory droplets produced when an infected person coughs. These droplets can land in the mouths, noses, or eyes of people who are nearby or possibly be inhaled into the lungs. Currently, the extent to which touching a surface or object that has the virus on it and then touching their own mouth, nose, or possibly their eyes, contributes to transmission is unclear.

Purpose
This interim guidance is intended to assist with assessment of risk, monitoring, and work restriction decisions for HCP with potential exposure to 2019-nCoV. For guidance on assessment and management of exposure risk in non-healthcare settings, refer to the Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus (2019-nCoV) Exposure in Travel-associated or Community Settings. The guidance for non-healthcare settings can also be used to identify the movement, public activity and travel restrictions that apply to the HCP included here.

Because of their often extensive and close contact with vulnerable individuals in healthcare settings, a conservative approach to HCP monitoring and restriction from work was taken to quickly identify early symptoms and prevent transmission from potentially contagious HCP to

- Facilities must be prepared to appropriately assess risk exposures, track, monitor and exclude exposed HCPs in collaboration with public health.
- Healthcare facilities must immediately report any at-risk HCP who develops symptoms to DOH at 877-PA-HEALTH or your local health department.
patients, HCP, and others visiting or working in a healthcare setting. For this reason, the signs and symptoms* described in this guidance are more inclusive than those described when assessing exposures for individuals not working in healthcare. Healthcare facilities should have a low threshold for evaluating symptoms and testing symptomatic HCP, particularly those who fall into the high- and medium-risk categories described in this guidance.

This guidance is based on the currently limited information available about 2019-nCoV. Based on these uncertainties, the recommendations regarding which HCP are restricted from work may not prevent all transmission or anticipate every potential scenario, and will change if indicated by new information.

Healthcare facilities, in consultation with public health authorities should use clinical judgement as well as the principles outlined in this guidance to assign risk and determine need for work restrictions. Please call DOH (877-PA-HEALTH) or your local health department to discuss any possible exposures. This cautious approach will be refined and updated as more information becomes available and as response needs change in the United States.

Other Resources

For infection prevention and control guidance for healthcare settings caring for Persons with Known or Under Investigation (PUI) for 2019 Novel Coronavirus (2019-nCoV), refer to the Interim Infection Prevention and Control Recommendations for Patients with Known or Patients Under Investigation for 2019 Novel Coronavirus (2019-nCoV) in a Healthcare Setting.

I. Definitions Used in this Guidance

Self-monitoring means HCP should monitor themselves for fever by taking their temperature twice a day and remain alert for respiratory symptoms (e.g., cough, shortness of breath, sore throat)*. Anyone on self-monitoring should be provided a plan for whom to contact if they develop fever or respiratory symptoms during the self-monitoring period to determine whether medical evaluation is needed.

Active monitoring means that the state or local public health authority assumes responsibility for establishing regular communication with potentially exposed people to assess for the presence of fever or respiratory symptoms (e.g., cough, shortness of breath, sore throat)*. For HCP with high- or medium-risk exposures, CDC recommends this communication occurs at least once each day. The mode of communication can be determined by the state or local public health authority and may include telephone calls or any electronic or internet-based means of communication.

For HCP, active monitoring can be delegated by the health department to the HCP’s healthcare facility occupational health or infection control program, if both the health department and the facility are in agreement. Note, inter-jurisdictional coordination and awareness will be needed if HCP live in a different local health jurisdiction than where the healthcare facility is located.
**Self-Monitoring with delegated supervision** in a healthcare setting means HCP perform self-monitoring with oversight by their healthcare facility’s occupational health or infection control program in coordination with the health department of jurisdiction, if both the health department and the facility are in agreement. Occupational health or infection control personnel should establish points of contact between the organization, the self-monitoring personnel, and DOH or the local health department in the location where self-monitoring personnel will be during the self-monitoring period. This communication should result in agreement on a plan for medical evaluation of personnel who develop fever or respiratory symptoms (e.g., cough, shortness of breath, sore throat)* during the self-monitoring period. The plan should include instructions for notifying occupational health and the local public health authority, and transportation arrangements to a designated hospital, if medically necessary, with advance notice if fever or respiratory symptoms occur. The supervising organization should remain in contact with HCP through the self-monitoring period to oversee self-monitoring activities. Note, inter-jurisdictional coordination will be needed if HCP live in a different local health jurisdiction than where the healthcare facility is located.

**Close contact** for healthcare exposures is defined as follows: a) being within approximately 6 feet (2 meters), of a person with 2019-nCoV infection for a prolonged period of time (such as caring for or visiting the patient; or sitting within 6 feet of the patient in a healthcare waiting area or room); or b) having unprotected direct contact with infectious secretions or excretions of the patient (e.g., being coughed on, touching used tissues with a bare hand).

Data to inform the definition of close contact are limited. Considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk), clinical symptoms of the patient (e.g., coughing likely increases exposure risk) and whether the patient was wearing a facemask (which can efficiently block respiratory secretions from contaminating others and the environment). It is not possible to define the duration of time that constitutes a prolonged exposure. However, until more is known about transmission risks, it would be reasonable to consider anything longer than a brief (e.g., less than 1 to 2 minutes) exposure as prolonged.

Currently brief interactions are considered to be less likely to result in transmission; however, as described above, this is dependent on the clinical symptoms of the patient and type of interaction (e.g., did the patient cough directly into the face of the HCP). Information about this will be updated as more information becomes available. Risk stratification can be made in consultation with public health authorities. Examples of brief interactions include: briefly entering the patient room without having direct contact with the patient or their secretions/excretions, brief conversation at a triage desk with a patient who was not wearing a facemask. See Table 1 for more detailed information.

**Healthcare Personnel:** For the purposes of this document HCP refers to all paid and unpaid persons serving in healthcare settings who have the potential for direct or indirect exposure to patients or infectious materials, including body substances; contaminated medical supplies, devices, and equipment; contaminated environmental surfaces; or contaminated air. For this document, HCP does not include clinical laboratory personnel.

**II. Defining Exposure Risk Category**
While body fluids other than respiratory secretions have not been clearly implicated in transmission of 2019-nCoV, unprotected contact with other body fluids, including blood, stool,
vomit, and urine, should also be considered as potentially putting HCP at risk of 2019-nCoV infection, until further data are available.

When assigning risk, factors to consider include: the duration of exposure (e.g., longer exposure time likely increases exposure risk), clinical symptoms of the patient (e.g., coughing likely increases exposure risk), whether the patient was wearing a facemask (which can efficiently block respiratory secretions from contaminating others and the environment), whether an aerosol generating procedure was performed, and the type of PPE used by HCP. However, data on the risk of transmission of 2019-nCoV are currently incomplete and the precision of current risk assignment is limited. Table 1 describes possible scenarios that can be used to assist with risk assessment. These scenarios do not cover all potential exposure scenarios and should not replace an individual assessment of risk for the purpose of clinical decision making or individualized public health management. Any public health decisions that place restrictions on an individual’s or group’s movements or impose specific monitoring requirements should be based on an assessment of risk for the individual or group. Healthcare facilities, in consultation with public health authorities should use the concepts outlined in this guidance along with clinical judgement to assign risk and determine need for work restrictions.

For this guidance high-risk exposures refer to HCP who performed or were present in the room for procedures that generate aerosols or during which respiratory secretions are likely to be poorly controlled (e.g., cardiopulmonary resuscitation, intubation, extubation, bronchoscopy, nebulizer therapy, sputum induction) on patients with 2019-nCoV when the healthcare providers’ eyes, nose, or mouth were not protected.

Medium-risk exposures generally include HCP who had prolonged close contact with patients with 2019-nCoV where HCP mucous membranes or hands were exposed to material potentially infectious with 2019-nCoV. These exposures could place the exposed HCP at risk of developing disease that is less than that described under high-risk.

Proper adherence to currently recommended infection control practices, including all recommended PPE, should protect HCP having prolonged close contact with patients infected with 2019-nCoV. However, HCP in this category are classified as having low-risk to account for any inconsistencies in use or adherence that could result in unrecognized exposures.

HCP with no direct patient contact and no entry into active patient management areas who adhere to routine safety precautions are not considered to have a risk of exposure to 2019-nCoV (i.e., they have no identifiable risk.)

Currently the guidance is intended to apply to HCP with potential exposure in a healthcare setting to patients with confirmed 2019-nCoV infection. However, HCP exposures will commonly involve a PUI who is awaiting testing. Implementation of the monitoring and work restrictions described in this guidance could be applied to HCP exposed to a PUI if test results for the PUI are not expected to return within 48 to 72 hours. A record of HCP exposed to the PUI should still be maintained and HCP should be encouraged to perform self-monitoring while awaiting test results. If the results will be delayed more than 72 hours or the patient is positive for 2019-nCoV then all monitoring and work restrictions described in this document should be followed.
Table 1: Epidemiologic Risk Classification\(^1\) for Asymptomatic Healthcare Personnel Following Exposure to Patients with 2019 Novel Coronavirus (2019-nCoV) Infection or their Secretions/Excretions in a Healthcare Setting, and their Associated Monitoring and Work Restriction Recommendations

The distinction between the high- and medium-risk exposures in this document is somewhat artificial as they both place HCP at risk for developing infection; therefore the recommendations for active monitoring and work restrictions are the same for these exposures. However, these risk categories were created to align with risk categories described in the Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus (2019-nCoV) Exposure in Travel-associated or Community Settings, which outlines criteria for quarantine and travel restrictions specific to high-risk exposures. Refer to that Interim Guidance for information about the movement, public activity and travel restrictions that apply to the HCP included here.

The highest risk exposure category that applies should be used to guide monitoring and work restrictions.

<table>
<thead>
<tr>
<th>Epidemiologic risk factors</th>
<th>Exposure category</th>
<th>Recommended Monitoring for 2019-nCoV (until 14 days after last potential exposure)</th>
<th>Work Restrictions for Asymptomatic HCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. HCP (with unprotected eyes, nose, or mouth) who perform or are present in the room for a procedure likely to generate higher concentrations of respiratory secretions or aerosols (e.g., cardiopulmonary resuscitation, intubation, extubation, bronchoscopy, nebulizer therapy, sputum induction)</td>
<td>High</td>
<td>Active</td>
<td>Exclude from work for 14 days after last exposure</td>
</tr>
<tr>
<td>B. HCP who perform or are present in the room for a procedure likely to generate higher concentrations of respiratory secretions or aerosols (e.g., cardiopulmonary resuscitation, intubation, extubation, bronchoscopy, nebulizer therapy, sputum induction) and not using a gown and gloves.</td>
<td>Medium</td>
<td>Active</td>
<td>Exclude from work for 14 days after last exposure</td>
</tr>
</tbody>
</table>

Note: If the HCP’s eyes, nose, or mouth were also unprotected they would fall into the high-risk category above.
<table>
<thead>
<tr>
<th>Epidemiologic risk factors</th>
<th>Exposure category</th>
<th>Recommended Monitoring for 2019-nCoV (until 14 days after last potential exposure)</th>
<th>Work Restrictions for Asymptomatic HCP</th>
</tr>
</thead>
</table>
| C. HCP (with unprotected eyes, nose, or mouth) who have prolonged close contact with a patient *who was not wearing a facemask*  
Note: A respirator confers a higher level of protection than a facemask. However, they are grouped together in this scenario because (even if a respirator or facemask was worn) the eyes remain uncovered while having prolonged close contact with a patient *who was not wearing a facemask*. | Medium | Active | Exclude from work for 14 days after last exposure |
| D. HCP (with unprotected eye, nose, and mouth) who have prolonged close contact with a patient *who was wearing a facemask* | Medium | Active | Exclude from work for 14 days after last exposure |
| E. HCP (not wearing gloves) who have direct contact with the secretions/excretions of a patient and the HCP failed to perform immediate hand hygiene  
Note: If the HCP performed hand hygiene immediately after contact, this would be considered low risk. | Medium | Active | Exclude from work for 14 days after last exposure |
| F. HCP wearing a facemask or respirator only who have prolonged close contact with a patient *who was wearing a facemask*  
Note: A respirator confers a higher level of protection than a facemask. However, they are grouped together in this scenario and classified as low-risk because the patient was wearing a facemask for source control. | Low | Self with delegated supervision | None |
<p>| G. HCP using all recommended PPE (i.e., a respirator, eye protection, gloves and a gown) while caring for | Low | Self with delegated supervision | None |</p>
<table>
<thead>
<tr>
<th>Epidemiologic risk factors</th>
<th>Exposure category</th>
<th>Recommended Monitoring for 2019-nCoV (until 14 days after last potential exposure)</th>
<th>Work Restrictions for Asymptomatic HCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>or having contact with the secretions/excretions of a patient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>H. HCP (not using all recommended PPE) who have brief interactions with a or patient regardless of whether patient was wearing a facemask (e.g., brief conversation at a triage desk; briefly entering a patient room but not having direct contact with the patient or their secretions/excretions; entering the patient room immediately after they have been discharged)</td>
<td>Low</td>
<td>Self with delegated supervision</td>
<td>None</td>
</tr>
<tr>
<td>I. HCP who walk by a patient or who have no direct contact with the patient or their secretions/excretions and no entry into the patient room</td>
<td>No identifiable risk</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

HCP=healthcare personnel; PPE=personal protective equipment

1 The distinction between the high- and medium-risk exposures in this document is somewhat artificial as they both place HCP at risk for developing infection and the recommendations for active monitoring and work restrictions are the same for these exposures. However, these risk categories were created to align with risk categories described in the Interim US Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus (2019-nCoV) Exposure in Travel-associated or Community Settings, which outlines criteria for quarantine and travel restrictions specific to high-risk exposures. Refer to that Interim Guidance for information about the movement, public activity and travel restrictions that apply to the HCP included here.

III. Recommendations for Monitoring Based on 2019-nCoV Exposure Risk

Collaborate with DOH (877-PA-HEALTH) or your local health department to assess risk exposures, track, monitor and exclude exposed HCPs in collaboration with public health.

HCP in any of the risk exposure categories who develop signs or symptoms compatible with 2019-nCoV infection must contact DOH (877-PA-HEALTH) or your local health department immediately. The discussion by public health authorities in Pennsylvania will assist the HCP’s medical evaluation.
Please note that this updated CDC guidance defines a low threshold for fever (measured temperature ≥100.0°F or subjective fever) for increased sensitivity.

1. High- and Medium-risk Exposure Category

HCP in the high- or medium-risk category should undergo active monitoring, including restriction from work in any healthcare setting until 14 days after their last exposure. If they develop any fever (measured temperature ≥100.0°F or subjective fever) OR respiratory symptoms consistent with 2019-nCoV infection (e.g., cough, shortness of breath, sore throat)* they should immediately self-isolate (separate themselves from others) and notify DOH or their local health department and healthcare facility promptly so that they can coordinate consultation and referral to a healthcare provider for further evaluation.

2. Low-risk Exposure Category

HCP in the low-risk category should perform self-monitoring with delegated supervision until 14 days after the last potential exposure. Asymptomatic HCP in this category are not restricted from work. They should check their temperature twice daily and remain alert for respiratory symptoms consistent with 2019-nCoV infection (e.g., cough, shortness of breath, sore throat)*. They should ensure they are afebrile and asymptomatic before leaving home and reporting for work. If they do not have fever or respiratory symptoms they may report to work. They should have their temperature retaken and symptoms assessed by the healthcare facility each day before starting work. On days they are not working they are not required to report unless they develop symptoms. If they develop fever (measured temperature ≥ 100.0 °F or subjective fever) OR respiratory symptoms they should immediately self-isolate (separate themselves from others) and notify DOH or their local health department and healthcare facility promptly so that they can coordinate consultation and referral to a healthcare provider for further evaluation.

3. No Identifiable risk Exposure Category

HCP in the no identifiable risk category do not require monitoring or restriction from work.

4. Community or travel-associated exposures

HCP with potential exposures to 2019-nCoV in community settings, should have their exposure risk assessed according CDC guidance. Collaborate with DOH (877-PA-HEALTH) or your local health department to assess the risk. HCP who fall into the high- or medium- risk category described there should undergo monitoring as defined by DOH or their local health department and be excluded from work in a healthcare setting until 14 days after their exposure. HCP who develop signs or symptoms compatible with 2019-nCoV should contact their established point of contact (DOH or their local health department and their facility’s occupational health program) for medical evaluation prior to returning to work.
Pennsylvania Department of Health Summary

Healthcare facilities **must notify PADOH or the local health department** to conduct a risk assessment of the nature of the exposure. All HCPs, except those with no identifiable risk (Box I of the table above), who are exposed to patients with known or suspected 2019-nCoV infection will need this risk assessment to decide on recommended monitoring and work restrictions.

**Those staff with high and medium risk exposures have to be excluded from work for 14 days after the last exposure. Those with low risk exposures should not be restricted from work.**

HCP with close contact with proper PPE and engineering controls should be protected and are assigned a low risk category to be conservative and protective to account for any inconsistencies in the use or adherence that result in unrecognized exposures.

**All HCP’s with identifiable exposures (i.e., low, medium high) will need to be monitored in collaboration with public health.**

- Those with high and medium risk exposures need to be actively monitored
- Those with low risk exposures need to self-monitor with delegated supervision

This guidance applies to HCPs exposed to confirmed cases. Laboratory results for PUIs are expected within 48-72 hours. However, monitoring and work exclusions should be implemented for potentially exposed HCPs if PUI test results are delayed beyond 72 hours.

A recently published *JAMA* paper\(^a\) determined that there was alleged human-to-human transmission at a hospital in Wuhan. This is an early report of a large case series that gives us essential information about how diseases spread in hospital settings. It is important to monitor this situation so we can prepare to take prevention measures against outbreaks at these facilities in the future.

**Please call DOH (877-PA-HEALTH) or your local health department for any concerns about HCPs who may have been exposed to patients with 2019-nCoV.**


Categories of Health Alert messages:
- **Health Alert**: conveys the highest level of importance; warrants immediate action or attention.
- **Health Advisory**: provides important information for a specific incident or situation; may not require immediate action.
- **Health Update**: provides updated information regarding an incident or situation; unlikely to require immediate action.

This information is current as of February 9, 2020 but may be modified in the future. We will continue to post updated information regarding the most common questions about this subject.